* alt / ast\> 5 times the normal limit * stage 4 chronic kidney disease (gfr \<30) or requiring dialysis. * presence of comorbidities that imply a poor prognosis (according to clinical judgment). * advanced dementia. * pregnancy or breastfeeding. * anticipation of transfer to another center in the 12 hours at the beginning of the study. * allergy to study medication. * serious or active bacterial infections or documented sepsis by pathogens other than sars-cov-2. * streptococcus pneumoniae antigenuria positive before study start. * neutropenia \<500 / mm3. * thrombocytopenia \<100,000 / mm3. * history of diverticulosis. * ongoing skin infection (eg, pyodermitis). * transplanted patient under immunosuppressive treatment. * previous evidence of latent untreated tuberculosis.

* alt / ast\> 5 times the normal limit * stage 4 chronic kidney disease (gfr \<30) or requiring dialysis. * presence of comorbidities that imply a poor prognosis (according to clinical judgment). * advanced dementia. * pregnancy or breastfeeding. * anticipation of transfer to another center in the 12 hours at the beginning of the study. * allergy to study medication. * serious or active bacterial infections or documented sepsis by pathogens other than sars-cov-2. * streptococcus pneumoniae antigenuria positive before study start. * neutropenia \<500 / mm3. * thrombocytopenia \<100,000 / mm3. * history of diverticulosis. * ongoing skin infection (eg, pyodermitis). * transplanted patient under immunosuppressive treatment. * previous evidence of latent untreated tuberculosis.

- alt / ast> 5 times the normal limit - stage 4 chronic kidney disease (gfr <30) or requiring dialysis. - presence of comorbidities that imply a poor prognosis (according to clinical judgment). - advanced dementia. - pregnancy or breastfeeding. - anticipation of transfer to another center in the 12 hours at the beginning of the study. - allergy to study medication. - serious or active bacterial infections or documented sepsis by pathogens other than sars-cov-2. - streptococcus pneumoniae antigenuria positive before study start. - neutropenia <500 / mm3. - thrombocytopenia <100,000 / mm3. - history of diverticulosis. - ongoing skin infection (eg, pyodermitis). - transplanted patient under immunosuppressive treatment. - previous evidence of latent untreated tuberculosis.

- alt / ast> 5 times the normal limit - stage 4 chronic kidney disease (gfr <30) or requiring dialysis. - presence of comorbidities that imply a poor prognosis (according to clinical judgment). - advanced dementia. - pregnancy or breastfeeding. - anticipation of transfer to another center in the 12 hours at the beginning of the study. - allergy to study medication. - serious or active bacterial infections or documented sepsis by pathogens other than sars-cov-2. - streptococcus pneumoniae antigenuria positive before study start. - neutropenia <500 / mm3. - thrombocytopenia <100,000 / mm3. - history of diverticulosis. - ongoing skin infection (eg, pyodermitis). - transplanted patient under immunosuppressive treatment. - previous evidence of latent untreated tuberculosis.